An HRCT of the chest should be obtained before the initiation of EGFR-TKI therapy because pre-existing pulmonary abnormalities, such as lung fibrosis, are associated with an increased risk of ILD [30]. This evidence concerns the gene EGFR and interstitial lung disease.